VAI TRÒ CỦA THUỐC SINH HỌC TRONG ĐIỀU TRỊ BỆNH BẠCH CẦU CẤP DÒNG LYMPHO: XU HƯỚNG CÁ THỂ HÓA ĐIỀU TRỊ
Objective: An overview of the role of biologics and the trend towards individualized treatment of acute lymphoblastic leukemia.Methods: This study synthesizes scientific knowledge and perspectives according to PRISMA guidelines, using secondary literature from reputable health organizations and 10 English-language studies analyzed using narrative synthesis.Results: A comprehensive review of 10 studies shows that biologic agents (blinatumomab, inotuzumab ozogamicin, and CAR-T cell therapy) improve the rate of minimal residual disease (MRD) negativity, reaching up to 93%. Combination regimens incorporating tyrosine kinase inhibitors (TKIs) and monoclonal antibodies have opened the way to a chemotherapy-free paradigm as frontline therapy for Philadelphia chromosome-positive (Ph+) ALL, achieving complete remission (CR) rates of 98%. Furthermore, dual-targeting CAR-T technology has been developed to overcome drug resistance mechanisms.Conclusion: Biologic therapies represent a revolutionary advancement and serve as the cornerstone of the modern trend toward personalized treatment of acute lymphoblastic leukemia (ALL). The application of targeted therapies and advanced cellular approaches enables the eradication of leukemic cells at the molecular level, establishing MRD assessment as an important prognostic marker for survival and helping to replace the previous one-size-fits-all chemotherapy regimens.
Authors
- Triều Vỉ Võ
- Thị Ly Ly Ngọc Vũ
- A Nữ Vũ Quỳnh Trịnh
- Minh Quang Trần
Publication Details
- Journal
- Journal of Clinical Medicine Bach Mai Hospital
- Published
- 2026-11-21
- DOI
- https://doi.org/10.52322/jocmbmh.156.0201
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00